Patents by Inventor James Cardia

James Cardia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY
    Publication number: 20230089478
    Abstract: The disclosure relates, in some aspects, to methods and compositions for targeting chemically-modified double stranded nucleic acid molecules to a site of interest, such as the liver. In some embodiments, compositions and methods described by the disclosure are useful for treating hepatic cancers or other liver diseases.
    Type: Application
    Filed: December 31, 2020
    Publication date: March 23, 2023
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: James Cardia, Dingxue Yan
  • RNA interference in ocular indications
    Patent number: 11584933
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 21, 2023
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY
    Publication number: 20230002766
    Abstract: The disclosure relates, in some aspects, to methods and compositions for production of immunomodulatory compositions. In some embodiments, the disclosure provides host cells which have been treated ex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiation of the host cell. In some embodiments, compositions and methods described by the disclosure are useful as immunogenic modulators for treating cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 5, 2023
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: James Cardia, Rolf Kiessling, Jeroen Melief
  • Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
    Patent number: 11279934
    Abstract: Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: March 22, 2022
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Michael Byrne, Karen G. Bulock, James Cardia
  • Reduced size self-delivering RNAI compounds
    Patent number: 11118178
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20210261968
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
    Patent number: 11021707
    Abstract: The present disclosure relates to RNAi constructs with improved cellular uptake characteristics and methods of use of these compounds for silencing expression of long coding RNAs (IncRNAs).
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: June 1, 2021
    Assignees: Phio Pharmaceuticals Corp., Biogazelle NV
    Inventors: James Cardia, Karen G. Bulock, Joke Hedwig Vandesompele, Gert Van Peer
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20210147849
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: July 21, 2020
    Publication date: May 20, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
    Patent number: 11001845
    Abstract: Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase 1 (SOD1).
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 11, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: James Cardia, Michael Byrne, Karen G. Bulock, Pamela A. Pavco, Lyn Libertine
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20210062195
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: May 12, 2020
    Publication date: March 4, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA interference in dermal and fibrotic indications
    Patent number: 10913948
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Reduced size self-delivering RNAI compounds
    Patent number: 10876119
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in skin indications
    Patent number: 10815485
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: October 27, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAI compounds
    Patent number: 10774330
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 15, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 10662430
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20200002701
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: February 7, 2019
    Publication date: January 2, 2020
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20190233826
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: November 30, 2018
    Publication date: August 1, 2019
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20190161757
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 30, 2019
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 10240149
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 26, 2019
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • REDUCED SIZE SELF-DELIVERING NUCLEIC ACID COMPOUNDS TARGETING LONG NON-CODING RNA
    Publication number: 20190048341
    Abstract: The present disclosure relates to RNAi constructs with improved cellular uptake characteristics and methods of use of these compounds for silencing expression of long coding RNAs (IncRNAs).
    Type: Application
    Filed: October 19, 2016
    Publication date: February 14, 2019
    Applicants: RXi Pharmaceuticals Corporation, Biogazelle NV
    Inventors: James Cardia, Karen G. Bulock, Joke Hedwig Vandesompele, Gert Van Peer